Navigation Links
Advisory Committee Briefing Materials for CRESTOR(R) sNDA Available on US FDA Web Site
Date:12/11/2009

ncreased cardiovascular risk as identified by age and elevated high-sensitivity C-reactive protein (hsCRP). The majority of patients had at least one other risk factor including hypertension, low HDL-C, family history of premature coronary heart disease (CHD) or smoking. hsCRP is a recognized marker of inflammation which is associated with an increased risk of atherosclerotic cardiovascular events.

JUPITER is a part of AstraZeneca's extensive GALAXY clinical trials program, designed to address important unanswered questions in statin research. Currently, more than 65,000 patients have been recruited from 55 countries worldwide to participate in the GALAXY Program.

ABOUT CRESTOR (ROSUVASTATIN CALCIUM):

CRESTOR is indicated as an adjunct to diet to reduce elevated Total-C, LDL-C, ApoB, non-HDL-C, and TG levels and to increase HDL-C in patients with primary hyperlipidemia and mixed dyslipidemia. CRESTOR is also indicated as an adjunct to diet to slow the progression of atherosclerosis in adult patients as part of a treatment strategy to lower Total-C and LDL-C to target levels. CRESTOR is not approved to reduce cardiovascular morbidity and mortality.

IMPORTANT SAFETY INFORMATION:

CRESTOR is contraindicated in patients with a known hypersensitivity to any component of this product, in patients with active liver disease, which may include unexplained persistent elevations of hepatic transaminase levels, in women who are pregnant or may become pregnant, and in nursing mothers.

Cases of myopathy and rhabdomyolysis with acute renal failure secondary to myoglobinuria have been reported with HMG-CoA reductase inhibitors, including CRESTOR. These risks can occur at any dose level, but are increased at the highest dose (40 mg).

CRESTOR should be prescribed with caution in patients with predisposing factors for myopathy (eg, age greater than or equal to 65 years, inadequately treated hyp
'/>"/>

SOURCE AstraZeneca
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. FDA Advisory Committees Recommend Continued U.S. Marketing Authorization for Trasylol(R)
2. Statement by KCP Chairman Dr. Edward Jones in Response to FDA Advisory Committee on Benefits and Risks of Erythropoietin-Stimulating Agents in Treatment of Kidney Patients
3. Targeted Genetics Reports on Recombinant DNA Advisory Committee (RAC) Review of its Phase 1/2 Trial of tgAAC94 for Rheumatoid Arthritis
4. Schiffrin Barroway Topaz & Kessler, LLP and Janet Jenner & Suggs, LLC Comment on Conagra Advisory Regarding Pot Pies Linked to Salmonella Outbreak
5. Solvay Pharmaceuticals, Inc. Responds to Advisory Committee Recommendation for Further Study of Tedisamil to Treat Atrial Fibrillation
6. FDA Advisory Committee Supports Efficacy and Safety of Zyprexa(R) Long-Acting Injection (LAI) for Schizophrenia Treatment
7. HUYA Bioscience Intl Announces World-Class Clinical Advisory Team for New Anti-Arrhythmic Compound Sourced From China
8. FDA Advisory Committee Unanimously Recommends U.S. Approval of Sugammadex, the First and Only Selective Relaxant Binding Agent
9. Ortho Biotech Statement on U.S. Food and Drug Administration Oncologic Drugs Advisory Committee Vote
10. UBC Forms European Advisory Board to Enhance Data Quality of CNS Trials
11. FDA Advisory Committee Unanimously Recommends Approval of Ustekinumab for Treatment of Moderate to Severe Plaque Psoriasis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)...  Decision Resources Group is launching an extension of ... now include ChinaTrack; the new capabilities track the ... dashboard providing detailed brand-level share tracking and analytics. ChinaTrack ... Other key capabilities of the new line ... to end-user surveys of healthcare facilities, ChinaTrack data is ...
(Date:7/31/2014)... BURLINGTON, Mass. , July 31, 2014 /PRNewswire/ ... committee members—who make decisions about which therapies are ... influence formulary placement, according to a new Manhattan ... Makers 2014 . The study finds that P&T ... and pharmacy benefits managers (PBMs) have set a ...
(Date:7/31/2014)... July 31, 2014 Touro University California,s College ... selected as the recipient of a $150,000 grant by ... the University to increase research and classroom space on ... technology for the study of health sciences, and will ... needs and interests of our students," said Shelley ...
Breaking Medicine Technology:Decision Resources Group Announces First Medical Device Account Targeting Tool in China 2Formulary Decision Makers Say Pharma-Provided Patient Support Solutions Influence Formulary Placement 2Formulary Decision Makers Say Pharma-Provided Patient Support Solutions Influence Formulary Placement 3Touro University California Garners Grant From Long Foundation 2
... Oct. 23 Optimer Pharmaceuticals, Inc. (Nasdaq: ... from its two fidaxomicin Phase 3 trials in patients ... 48th Annual Meeting of the Infectious Disease Society of ... oral presentation, investigator Derrick Crook, M.D., of the University ...
... 22 Amedisys, a leading home health care and hospice company ... on the future of home care in this week,s issue of ... of the Amedisys Strategic Advisory Board. Titled, "Why ... on the future of home care as an increasingly crucial component ...
Cached Medicine Technology:Optimer Pharmaceuticals Announces Combined Data From Fidaxomicin Phase 3 Trials for the Treatment of Clostridium difficile Infection (CDI) Presented at IDSA 2Optimer Pharmaceuticals Announces Combined Data From Fidaxomicin Phase 3 Trials for the Treatment of Clostridium difficile Infection (CDI) Presented at IDSA 3Optimer Pharmaceuticals Announces Combined Data From Fidaxomicin Phase 3 Trials for the Treatment of Clostridium difficile Infection (CDI) Presented at IDSA 4Optimer Pharmaceuticals Announces Combined Data From Fidaxomicin Phase 3 Trials for the Treatment of Clostridium difficile Infection (CDI) Presented at IDSA 5Media Statement From Amedisys on Dr. Steven H. Landers' NEJM Commentary on the Future of Home Care 2
(Date:7/31/2014)... Atlanta-based Jvion, a leader in clinical ... lessons in predictive population health analytics as part of ... analytics in healthcare. Ritesh Sharma, Jvion COO, commented, “it ... to understand the impact of and potential within predictive ... and a good portion of it is conflicting or ...
(Date:7/31/2014)... During the July 2014 board meeting of the ... executive director of the Mesothelioma Applied Research Foundation, Mary ... promising clinical trials to choose from than ever before. ... have been reporting increased survival and response rates. Some ... is within the field of immunotherapy. One trial, ...
(Date:7/31/2014)... ANN ARBORA new bill introduced in Congress with bipartisan ... from University of Michigan research, which could improve the ... they spend on the medicines and tests they need ... Reps. Diane Black and Earl Blumenauer, grew out of ... with the U-M,s Institute for Healthcare Policy and Innovation. ...
(Date:7/31/2014)... Jacuzzi Luxury Bath, the company ... a new and improved website to meet the needs ... Luxury Bath website has been redesigned to offer a ... represented by the company’s products. The design is current, ... bathroom applications. “The site reflects our Jacuzzi® brand standards, ...
(Date:7/31/2014)... drug, researchers at The Wistar Institute discovered that ... with fewer age-related illnesses. The mice, which lack ... degeneration, obesity, and spontaneous tumor formation when compared ... scientists view the metabolic networks within cells. ... regulator of metabolism and has been shown to ...
Breaking Medicine News(10 mins):Health News:Jvion Releases Top Three Lessons in Predictive Population Health Analytics 2Health News:Jvion Releases Top Three Lessons in Predictive Population Health Analytics 3Health News:‘More Promising Mesothelioma Clinical Trials than Ever Before,’ Says Expert 2Health News:‘More Promising Mesothelioma Clinical Trials than Ever Before,’ Says Expert 3Health News:Jacuzzi Luxury Bath Launches New and Improved Website 2Health News:'Rewired' mice show signs of longer lives with fewer age-related illnesses 2Health News:'Rewired' mice show signs of longer lives with fewer age-related illnesses 3
... planning to phase out junk food and make exercise mandatory, ... Department to counter childhood obesity//. , ,These recommendations follow ... were being sent to dieticians. , ,The NSW report, ... the biggest study of its kind in the country. The ...
... been awarded with discount shopping cards in return for ... clinic as part of the HIV/AIDS awareness program//. ... Nation's AIDS-prevention agency India has largest number of people, ... virus. ,Sushena Reza-Paul of the Karnataka Health ...
... Pradesh today in protest against dismissal of AIIMS director ... junior doctors observed a `symbolic' strike and a large ... some time condemning the sacking of Venugopal., ,Terming ... the strike was "symbolic and we have no intention ...
... Manchester is reportedly treating patients with mouth and throat cancer ... ,Sources at the Manchester cancer hospital explained that ... doctors at Christie Hospital in Didsbury, Manchester, are planning to ... clinical trail basis. They hope to try and reduce the ...
... expressed their concerns over the practice of "Breast Ironing" ... is used to stunt breast growth in girls by mothers// ... own good. ,It is aimed at warding off ... objects pressed against the developing breasts in teenaged girls. "Breast ...
... is brandishing a piece of his own skull, an ... visitors//. ,The Jawaharlal Nehru Memorial Hospital in Kalyani, ... no less visitors than any museum these days with ... getting electrocuted from a high-voltage wire, holding his own ...
Cached Medicine News:Health News:Man Holds Own Skull in Bengal Medical Miracle 2
Abdominal Binder w / Velcro...
Ideal for abdominal, flank, hip and thigh procedures....
Male high waisted compression girdle with CDIs Wonderfabric™...
This high waist tummy tuck girdle provides the same CDI Wonderfabric™ compression as the 8000 series....
Medicine Products: